Tzippy Shochat

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 220 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Raz Mutai, Tamar Barkan, Assaf Moore et al. · The Breast · 2021 · 137 citations · Full text

Medicine, Oncology, Breast Oncology +13

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Elizabeth Dudnik, Mor Moskovitz, Sameh Daher et al. · Lung Cancer · 2017 · 104 citations

Medicine, Oncology, Pharmacology +12

ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism

Alona Zer, Mor Moskovitz, David Hwang et al. · Clinical Lung Cancer · 2016 · 100 citations

Medicine, Genetics, Oncology +14

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)

Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein et al. · Lung Cancer · 2018 · 75 citations

Medicine, Immunology, Oncology +14